Developer docs
API playgroundTry for free, no card

Search company profiles

Sequel Pharmaceuticals

Full company profile

uuid000byqi

Namestring
Sequel Pharmaceuticals
Legal namestring
Sequel Pharma, LLC
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Sequel Pharma, LLC is a privately held specialty pharmaceutical company headquartered at 300 Interpace Parkway, Parsippany, New Jersey, that acquires, develops, and commercializes products in select therapeutic areas for the U.S. market. The firm operates a sales-led go-to-market model, distributing specialty pharmaceutical products through healthcare provider networks (hospitals, clinics, and physician practices), wholesalers, and pharmacies, rather than selling directly to consumers. Sequel Pharma employs between 11 and 50 people and is described in firmographic sources as focused on novel and clinical-stage drug candidates for cardiovascular disease, while the company's own website frames its scope more broadly as "select therapeutic areas" of specialty pharma commercialization.

The company is led by an experienced specialty-pharma management team rather than a proprietary technology platform. CEO Michael Anderson has 40+ years of pharmaceutical industry experience across branded products, generics, and medical instruments; he founded Eclat Pharmaceuticals in 2010 (sold to Flamel Technologies), then served as CEO of Flamel/Avadel Pharmaceuticals from 2012 to 2019, where the company progressed from no revenue and no profitability to a profitable specialty pharma with three approved NDAs. COO Phillandas Thompson, with an MBA and JD from the University of Michigan, spent 18 years in pharma including senior vice president, general counsel, and corporate secretary roles at Avadel Pharmaceuticals, plus legal leadership at West-Ward, Paddock, KV Pharmaceutical, and Barr Pharmaceuticals. The company does not publicly disclose a specific branded product portfolio on its website.

Sequel Pharma has raised approximately $25.4 million in disclosed equity capital across five funding events from 2007 through 2018, including a $20 million Series A in 2007 from Domain Associates, Forward Ventures, InterWest Partners, Montreux Equity Partners, and Skyline Ventures, follow-on tranches in 2009 and 2010, and a Deerfield Management relationship recorded in November 2018. The company does not publicly disclose revenue, product-level sales, pricing, or specific FDA-approved assets, and its current revenue scale and product pipeline status cannot be triangulated from public sources.

Short descriptiontext

Sequel Pharma, LLC is a privately held, Parsippany, NJ-based specialty pharmaceutical company that acquires, develops, and commercializes products in select therapeutic areas, distributing them through U.S. healthcare providers, pharmacies, and wholesalers under experienced pharma leadership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, cardiovascular therapeutics, drug commercialization, pharmaceutical licensing, clinical-stage drugs
Industry2 codes
PRIMARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAEAKAA
Formulary Management & Clinical Pharmacy Programs
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Sequel Pharma generates revenue through the commercialization of specialty pharmaceutical products. The company acquires, develops, and markets products in select therapeutic areas, generating revenue from product sales to healthcare providers, pharmacies, and healthcare systems.

sequelpharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sequel Pharma, LLC is a privately held specialty pharmaceutical company that acquires, develops, and markets pharmaceutical products in select therapeutic areas, with a focus on cardiovascular disease candidates. The company commercializes specialty drugs through healthcare provider networks, pharmacies, and healthcare systems rather than direct-to-consumer sales.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sequel Pharma LLC is a privately held, specialty pharmaceutical company that acquires, develops, and commercializes products in select therapeutic areas. The company operates as a single-focus specialty pharma business rather than a multi-module platform. Based in Parsippany, New Jersey, the company is led by experienced pharmaceutical executives and does not publicly list specific branded pharmaceutical products on its website. The contact page references TOPROL-XL (metoprolol succinate) in the context of a Melinta Therapeutics business inquiry, but this appears to be unrelated to Sequel Pharma's own portfolio.

Product and service1 record
1Cardiovascular Drug Candidates
CategorySpecialty Pharmaceuticals
Partnership2 partners
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Troon Technologies LLC is identified as the hosting and management provider for Sequel Pharma's website and digital infrastructure. This is a technical operations support relationship rather than a core business partnership.

Strategic tierMinorTypeOthers
Description

Melinta Therapeutics acquired U.S. rights to TOPROL-XL® (metoprolol succinate). For medical inquiries, adverse event reporting, safety-related information, or product complaints related to TOPROL-XL, contact Melinta Medical Information at +1 844-MED-MLNT.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sequel Pharmaceuticals

Specialty Pharmaceuticalssequelpharma.com

Sequel Pharma, LLC is a privately held, Parsippany, NJ-based specialty pharmaceutical company that acquires, develops, and commercializes products in select therapeutic areas, distributing them through U.S. healthcare providers, pharmacies, and wholesalers under experienced pharma leadership.

What Sequel Pharmaceuticals does

Sequel Pharma, LLC is a privately held specialty pharmaceutical company headquartered at 300 Interpace Parkway, Parsippany, New Jersey, that acquires, develops, and commercializes products in select therapeutic areas for the U.S. market. The firm operates a sales-led go-to-market model, distributing specialty pharmaceutical products through healthcare provider networks (hospitals, clinics, and physician practices), wholesalers, and pharmacies, rather than selling directly to consumers. Sequel Pharma employs between 11 and 50 people and is described in firmographic sources as focused on novel and clinical-stage drug candidates for cardiovascular disease, while the company's own website frames its scope more broadly as "select therapeutic areas" of specialty pharma commercialization.

The company is led by an experienced specialty-pharma management team rather than a proprietary technology platform. CEO Michael Anderson has 40+ years of pharmaceutical industry experience across branded products, generics, and medical instruments; he founded Eclat Pharmaceuticals in 2010 (sold to Flamel Technologies), then served as CEO of Flamel/Avadel Pharmaceuticals from 2012 to 2019, where the company progressed from no revenue and no profitability to a profitable specialty pharma with three approved NDAs. COO Phillandas Thompson, with an MBA and JD from the University of Michigan, spent 18 years in pharma including senior vice president, general counsel, and corporate secretary roles at Avadel Pharmaceuticals, plus legal leadership at West-Ward, Paddock, KV Pharmaceutical, and Barr Pharmaceuticals. The company does not publicly disclose a specific branded product portfolio on its website.

Sequel Pharma has raised approximately $25.4 million in disclosed equity capital across five funding events from 2007 through 2018, including a $20 million Series A in 2007 from Domain Associates, Forward Ventures, InterWest Partners, Montreux Equity Partners, and Skyline Ventures, follow-on tranches in 2009 and 2010, and a Deerfield Management relationship recorded in November 2018. The company does not publicly disclose revenue, product-level sales, pricing, or specific FDA-approved assets, and its current revenue scale and product pipeline status cannot be triangulated from public sources.

Sequel Pharmaceuticals firmographics

Firmographics
Name
Sequel Pharmaceuticals
Legal name
Sequel Pharma, LLC
Website
https://sequelpharma.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Sequel Pharma, LLC is a privately held, Parsippany, NJ-based specialty pharmaceutical company that acquires, develops, and commercializes products in select therapeutic areas, distributing them through U.S. healthcare providers, pharmacies, and wholesalers under experienced pharma leadership.
Ownership category
akta.pro rank

Sequel Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAEAKAA
Formulary Management & Clinical Pharmacy Programs

Keywords

  • Specialty pharmaceuticals
  • Cardiovascular therapeutics
  • Drug commercialization
  • Pharmaceutical licensing
  • Clinical-stage drugs

Where Sequel Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sequel Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

  1. Pharmaceutical product sales: Sequel Pharma generates revenue through the commercialization of specialty pharmaceutical products. The company acquires, develops, and markets products in select therapeutic areas, generating revenue from product sales to healthcare providers, pharmacies, and healthcare systems.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Sequel Pharmaceuticals product offering

Product offering

Core offering

Sequel Pharma, LLC is a privately held specialty pharmaceutical company that acquires, develops, and markets pharmaceutical products in select therapeutic areas, with a focus on cardiovascular disease candidates. The company commercializes specialty drugs through healthcare provider networks, pharmacies, and healthcare systems rather than direct-to-consumer sales.

Product overview

Sequel Pharma LLC is a privately held, specialty pharmaceutical company that acquires, develops, and commercializes products in select therapeutic areas. The company operates as a single-focus specialty pharma business rather than a multi-module platform. Based in Parsippany, New Jersey, the company is led by experienced pharmaceutical executives and does not publicly list specific branded pharmaceutical products on its website. The contact page references TOPROL-XL (metoprolol succinate) in the context of a Melinta Therapeutics business inquiry, but this appears to be unrelated to Sequel Pharma's own portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cardiovascular Drug Candidates

Companies that use Sequel Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Sequel Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sequel Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Troon Technologies LLCminorImplementation/ SI/ Consulting PartnerTroon Technologies LLC is identified as the hosting and management provider for Sequel Pharma's website and digital infrastructure. This is a technical operations support relationship rather than a core business partnership.
  • Melinta TherapeuticsminorOthersMelinta Therapeutics acquired U.S. rights to TOPROL-XL® (metoprolol succinate). For medical inquiries, adverse event reporting, safety-related information, or product complaints related to TOPROL-XL, contact Melinta Medical Information at +1 844-MED-MLNT.

Recent moves5 records

Expansion highlights5 records

Sequel Pharmaceuticals competitors and assessment

Company assessment

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights6 records

Customer concentration

Sequel Pharmaceuticals social profiles

Digital presence

Sequel Pharmaceuticals compliance and trust

Trust signal

Compliance1 record

Sequel Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sequel Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Sequel Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sequel Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sequel Pharmaceuticals

What does Sequel Pharmaceuticals do?

Sequel Pharma, LLC is a privately held specialty pharmaceutical company that acquires, develops, and markets pharmaceutical products in select therapeutic areas, with a focus on cardiovascular disease candidates. The company commercializes specialty drugs through healthcare provider networks, pharmacies, and healthcare systems rather than direct-to-consumer sales.

Is Sequel Pharmaceuticals a public or private company?

Sequel Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sequel Pharmaceuticals founded?

Sequel Pharmaceuticals was founded in 2007. It employs 1 to 10 people.

Where is Sequel Pharmaceuticals based?

Sequel Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

How does Sequel Pharmaceuticals make money?

One revenue line is on record: pharmaceutical product sales.

Does Sequel Pharmaceuticals have an API?

No public API is recorded for Sequel Pharmaceuticals.

What industry is Sequel Pharmaceuticals in?

Sequel Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAFALAC, Specialty Pharmacies (Complex/High-Cost Therapies), with a secondary code of HLAEAKAA, Formulary Management & Clinical Pharmacy Programs. Its NAICS code is 32541 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales